Ken Griffin Synaptogenix, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$0.16 - $0.3 $13,367 - $25,063
83,544 New
83,544 $15,000
Q4 2022

Feb 14, 2023
BUY
$1.02 - $7.33 $34,922 - $250,964
34,238 New
34,238 $39,000

Others Institutions Holding SNPX

# of Institutions
2
Shares Held
30.3K
Call Options Held
0
Put Options Held
0
View Full List

About Synaptogenix, Inc.

SNPX Quotes by TradingView
  • Ticker SNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,840,630
  • Market Cap $26M
  • Description
  • Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodeg...
More about SNPX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email